Skip to main content Skip to section navigation Skip to footer
  • About Us
      Company Overview
      Team
      Careers
  • Gene Therapies
      Our Approach
      Publications & Presentations
  • Patients
      Patients & Families
      Patient Spotlight
  • Pipeline & Programs
      OPGx-BEST1
      OPGx-LCA5
      Preclinical
  • Investors
  • Contact Us
Skip to main content Skip to section navigation Skip to footer
Opus Genetics, Inc. IR Overview
  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
  • Back to Corporate Site

Press Releases

Investors

  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
Aug 7, 2019 6:30 am EDT
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
Jul 22, 2019 8:00 am EDT
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
rss_feed News RSS
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • accessibilityAccessibility Statement
Opus Genetics, Inc. home Opus Genetics on LinkedIn

Sign up to receive our newsletter

By providing your email address, you consent to receive messages from Opus Genetics. View our Privacy Policy.

  • Gene Therapies
  • Patients & Families
  • Pipeline
  • About Us
  • Careers
  • Contact Us
  • Investors
© 2026 Opus Genetics, Inc.
  • Cookie Policy
  • Privacy Statement
Site by BKW